NEW YORK (GenomeWeb News) — Pikamab said today that it has exclusively licensed a pair of US patents from the Hospital for Special Surgery in New York to develop a theranostic product to help guide drug development and patient treatment for lupus and lupus nephritis.

The first US patent, No. 5,830,652, provides methods for determining the severity of lupus and lupus nephritis by correlating to the functional polymorphisms in FcGR genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.